Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer.

Autor:	Figueiredo JC; Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California. Jane.Figueiredo@cshs.org Karen.Reckamp@cshs.org Akil.Merchant@cshs.org., Merin NM; Division of Hematology and Cellular Therapy, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California., Hamid O; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California., Choi SY; Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, California., Lemos T; Division of Hematology and Cellular Therapy, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California., Cozen W; Division of Hematology/Oncology, Department of Medicine, Department of Pathology, School of Medicine, University of California Irvine, Orange, California., Nguyen N; Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California., Finster LJ; Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California., Foley J; Division of Hematology and Cellular Therapy, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California., Darrah J; Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California., Gong J; Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California., Paquette R; Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California., Mita AC; Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California., Vescio R; Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California., Mehmi I; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California., Basho R; Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California., Tourtellotte WG; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California., Huynh CA; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California., Melmed GY; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California., Braun J; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California., McGovern DPB; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California., Mengesha E; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California., Botwin G; F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, California., Prostko JC; Abbott Diagnostics, Lake Forest, Illinois., Frias EC; Abbott Diagnostics, Lake Forest, Illinois., Stewart JL; Abbott Diagnostics, Lake Forest, Illinois., Joung S; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California., Van Eyk J; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.; Advanced Clinical Biosystems Research Institute, Cedars-Sinai Medical Center, Los Angeles, California., Ebinger JE; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California., Cheng S; Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California., Sobhani K; Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California., Reckamp KL; Department of Medicine, Division of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, California. Jane.Figueiredo@cshs.org Karen.Reckamp@cshs.org Akil.Merchant@cshs.org., Merchant A; Division of Hematology and Cellular Therapy, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California. Jane.Figueiredo@cshs.org Karen.Reckamp@cshs.org Akil.Merchant@cshs.org.
Jazyk:	angličtina
Zdroj:	Cancer research [Cancer Res] 2021 Dec 15; Vol. 81 (24), pp. 6273-6280. Date of Electronic Publication: 2021 Nov 10.
DOI:	10.1158/0008-5472.CAN-21-3554
Abstrakt:	Longitudinal studies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine-induced immune responses in patients with cancer are needed to optimize clinical care. In a prospective cohort study of 366 (291 vaccinated) patients, we measured antibody levels [anti-spike (IgG-(S-RBD) and anti-nucleocapsid immunoglobulin] at three time points. Antibody level trajectories and frequency of breakthrough infections were evaluated by tumor type and timing of treatment relative to vaccination. IgG-(S-RBD) at peak response (median = 42 days after dose 2) was higher ( P = 0.002) and remained higher after 4 to 6 months ( P = 0.003) in patients receiving mRNA-1273 compared with BNT162b2. Patients with solid tumors attained higher peak levels ( P = 0.001) and sustained levels after 4 to 6 months ( P < 0.001) compared with those with hematologic malignancies. B-cell targeted treatment reduced peak ( P = 0.001) and sustained antibody responses ( P = 0.003). Solid tumor patients receiving immune checkpoint inhibitors before vaccination had lower sustained antibody levels than those who received treatment after vaccination ( P = 0.043). Two (0.69%) vaccinated and one (1.9%) unvaccinated patient had severe COVID-19 illness during follow-up. Our study shows variation in sustained antibody responses across cancer populations receiving various therapeutic modalities, with important implications for vaccine booster timing and patient selection. SIGNIFICANCE: Long-term studies of immunogenicity of SARS-CoV-2 vaccines in patients with cancer are needed to inform evidence-based guidelines for booster vaccinations and to tailor sequence and timing of vaccinations to elicit improved humoral responses. (©2021 The Authors; Published by the American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu